June S. Almenoff, M.D., Ph.D., Director
June S. Almenoff is currently COO and Chief Medical Officer at Innovate Biopharmaceuticals. Dr. Almenoff was previously President and Chief Medical Officer of Furiex Pharmaceuticals (FURX: Nasdaq) until FURX was acquired by Actavis in 2014. Formerly the Vice President in the Clinical Safety organization at GSK, June chaired a Pharma-FDA working group, and also worked in the area of scientific licensing. Prior to joining GSK, Dr. Almenoff served on the faculty of Duke University School of Medicine, where she is currently an adjunct Professor.
Nissim Darvish, M.D., Ph.D., Director
Nissim is a veteran of the life science industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. He spent eight years with Pitango Venture Capital, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents and authored over 20 publications.
Arie Giniger, Ph.D., Director
Dr. Giniger’s business career in the pharmaceutical and cosmetics fields spans more than 40 years. Beginning as a scientist with Schering Plough (USA), Dr. Giniger joined Taya Israel Cosmetic Company, first as a chemist and ultimately as Managing Director. He then joined Agis Group (Israel) as the Managing Director of their Careline Cosmetics division and then as Commercial Manager of the entire Agis Group. He is the founder of Private Cord Blood Bank, Sheba Medical Center, Israel’s largest umbilical cord blood bank. He received a B.Sc. in Chemistry from Israel’s Technion in Haifa and holds a Ph.D. in Pharmaceutical Sciences from Columbia University in New York.
Isaac Israel, Director
Mr. Israel currently serves as CEO of Kitov Pharmaceuticals (TASE:KTOV). Isaac is also the Vice President of Business Development at Capital Point Ltd., a company focused on funding high-tech ventures, primarily in medical devices, biotechnology & environmental technologies. Mr. Israel founded and managed BeeContact Communications, a public company in the field of cellular communications and Uneri Capital, a company that provides financial and business consulting services to start-up companies.
Ariel Moses, Director
Ariel is a Managing Partner and CFO at Agate Medical Investments. Agate has managed VC funds since 2007 and has focused on MedTech spanning 25 companies in Israel, Asia, the US, and Europe. Prior to joining Agate, Ariel founded and lead a FinTech company within one of Israel's leading investment corporations. Ariel has extensive experience in corporate finance and fund management and is a Board member in 6 MedTech companies. Formerly an active board member in 'Iscare' – a European healthcare company active in IVF, plastic surgery, IBD treatments, and general surgery – he successfully exited in 2017. Ariel holds a B.A. in Economics and an L.L.B. from the Hebrew University in Jerusalem.
Michael Rice, Director
Michael Rice is a Founding Partner of LifeSci Advisors and LifeSci Capital. Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael is a former Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets – including the structuring and execution of numerous transactions. Michael also served as a Managing Director at Banc of America specializing in large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
Andrew Salzman M.D., Director
Dr. Salzman received his medical education at Harvard Medical School, and did his pediatric internship and residency at Columbia University. He founded and led the Division of Critical Care Medicine at Cincinnati’s Children’s Hospital. Dr. Salzman invented and developed the first poly (ADP-ribose) polymerase inhibitor (INO-1001) and the first adenosine 1 receptor agonist (INO-8875) to enter clinical trials. In addition to 175 peer-reviewed scientific publications, Dr. Salzman holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices. Dr. Salzman founded and built Inotek Pharmaceuticals, a140-person biotech company, raised $80M in venture capital, and concluded a $600M license with Genentech. Dr. Salzman currently serves as Chairman of Radikal Therapeutics, Inc., Salzman Capital Ventures Ltd., and Respirometics Ltd.
Our team is balanced by responsible stewardship and innovative drive.
• OrbiMed Advisors
• Ofakim Hi-Tech Ventures
• CFH – Corporate Finance